Genomic transcriptional profiling identifies a candidate blood biomarker signature for the diagnosis of septicemic melioidosis

Table 4 Characteristics of patients in the independent test set 2

Sample ID	Age (years)	Sex	Bacterial isolation	Antibiotherapy before blood collection	Underlying diseases	Survival
Other sepsis (n = 7)
I027*	64	Female	E. coli ^†	Fortum, ceftriaxone	UGIB	Non-survivor
I028^‡	81	Female	Corynebacterium spp.	Ceftriaxone, fortum, clindamycin	T2D	Survivor
I029^‡	74	Female	S. aureus	Fortum, ceftriaxone, tazocin	Asthma, emphysema, ARF	Survivor
I031*	48	Male	Enterococcus spp.	Fortum	Urinary tract infection	Survivor
I032*	54	Female	E. faecium	Fortum, tazocin	T2D, respiratory failure	Non-survivor
I033*	63	Female	E. coli ^†	Tazocin, ceftriaxone, fortum	T2D, ovarian cancer	Survivor
I034*	43	Male	A. hydrophila ^†	Tazocin	-	Survivor
Septicemic melioidosis (n = 8)
M031*	49	Male	B. pseudomallei	Fortum, bactrim, tazocin	T2D	Non-survivor
M032*	54	Male	B. pseudomallei	Fortum, doxycycline, sulperazone	T2D	Non-survivor
M033*	44	Male	B. pseudomallei	Fortum, sulperazone, bactrim, ciprofloxacin	T2D	Survivor
M034*	40	Female	B. pseudomallei	Fortum, bactrim, ceftazidime, ceftriaxone	T2D	Survivor
M035*	56	Male	B. pseudomallei	Ceftriaxone, ceftazidime, fortum	COPD, T2D	Non-survivor
M036*	41	Female	B. pseudomallei	Ceftriaxone, ceftazidime	T2D	Non-survivor
M037*	42	Female	B. pseudomallei	Bactrim, fortum, cloxacillin	T2D	Survivor
M038*	49	Female	B. pseudomallei	Ceftriaxone, fortum, ceftazidime, levofloxacin	-	Non-survivor

*Community-acquired septicemia; ^‡hospital-acquired septicemia. ^†Positive by two sets of blood cultures. ARF, acute renal failure; COPD, chronic obstructive pulmonary disease; T2D, type 2 diabetes; UGIB, upper gastrointestinal bleeding.